S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Antibe Therapeutics Stock Forecast, Price & News

+0.01 (+1.86%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
25,943 shs
Average Volume
41,039 shs
Market Capitalization
$28.40 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATBPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Antibe Therapeutics logo

About Antibe Therapeutics

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace, and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$7.67 million
Book Value
$0.84 per share


Net Income
$-19.93 million
Net Margins
Pretax Margin




Free Float
Market Cap
$28.40 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.92 out of 5 stars

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Antibe Therapeutics (OTCMKTS:ATBPF) Frequently Asked Questions

Is Antibe Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Antibe Therapeutics stock.
View analyst ratings for Antibe Therapeutics
or view top-rated stocks.

Are investors shorting Antibe Therapeutics?

Antibe Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 102,000 shares, a decline of 42.3% from the October 31st total of 176,800 shares. Based on an average trading volume of 150,100 shares, the days-to-cover ratio is presently 0.7 days.
View Antibe Therapeutics' Short Interest

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Antibe Therapeutics

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) released its earnings results on Tuesday, November, 16th. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. Antibe Therapeutics had a negative net margin of 244.59% and a negative trailing twelve-month return on equity of 57.68%.
View Antibe Therapeutics' earnings history

What price target have analysts set for ATBPF?

6 brokerages have issued twelve-month price targets for Antibe Therapeutics' stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate Antibe Therapeutics' stock price to reach $4.50 in the next year. This suggests a possible upside of 720.9% from the stock's current price.
View analysts' price targets for Antibe Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the following people:
  • Daniel Legault, President, Chief Executive Officer & Director
  • Alain Wilson, Chief Financial Officer
  • John Lawrence Wallace, Director & Chief Scientific Officer
  • Joseph W. Stauffer, Chief Medical Officer
  • David Vaughan, Chief Development Officer

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPF."

How do I buy shares of Antibe Therapeutics?

Shares of ATBPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATBPF stock can currently be purchased for approximately $0.55.

How much money does Antibe Therapeutics make?

Antibe Therapeutics has a market capitalization of $28.40 million and generates $7.67 million in revenue each year. The company earns $-19.93 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Antibe Therapeutics have?

Antibe Therapeutics employs 47 workers across the globe.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is www.antibethera.com.

Where are Antibe Therapeutics' headquarters?

Antibe Therapeutics is headquartered at 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The company can be reached via phone at (416) 922-3460 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.